Global Anthrax Treatment Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143109
- Pages: 225
-
Format:
Short Description
Global Anthrax Treatment Market, By Type (Cutaneous Anthrax, Pulmonary Anthrax and Intestinal Anthrax), Route of Administration (Oral, Parenteral and Others), End User (Government Organization, Hospitals, Academic and Research Institutes, and Others), Country(U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg , Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific , Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Market Definition:
Anthrax is caused by a bacterium called Bacillus anthracis (B. anthracis). It is primarily a disease of livestock that become infected by ingesting spores found in soil. Humans usually become infected with anthrax by handling products of infected animals such as leather or wool or by inhaling anthrax spores from infected animal products. They can also become infected by eating undercooked meat from infected animals. Anthrax is not known to be spread person-to-person.
Three clinical forms of anthrax infection exist. Cutaneous anthrax is the most common, constituting over 95% of reported cases. An estimated 2000 cases of cutaneous anthrax occur worldwide annually and result from the entry of spores through skin abrasions.
The differential diagnosis of anthrax includes depending on the clinical features, relevant specimens include PCR, gram stain, and cultures, from blood, pleural fluid, site of ulceration, cerebrospinal fluid, and stool. A number of available techniques are available. Most assays are based on detecting the entire organism, organism antigens, or organism nucleic acid through one of the following techniques: culture-based conventional methods; immunological detection; nucleic-acid-based assays; ligand-based detection; and biosensors.
Market Segmentation:
Global anthrax treatment market is categorized based on type, route of administration and end user.
On the basis of type, the global anthrax treatment market is segmented into cutaneous anthrax, pulmonary anthrax and intestinal anthrax
On the basis of route of administration, global anthrax treatment market is segmented into oral, parenteral and others
On the basis of end user, global anthrax treatment market is segmented into government organization, hospitals, academic and research institutes, and others
Market Players
The key market players for global anthrax treatment market are listed below:
Alembic Pharmaceuticals
Integrated Bio Therapeutics Inc.
Sun Pharmaceutical Industries Ltd.
Zydus Group
Bayer AG
Pfizer Inc.
EMERGENT
Sanofi
Elusys Therapeutics
Porton Biopharma
Lupin, Soligenix
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
ARISTO Pharmaceuticals Private Limited
INDOCO REMEDIES LTD.
Paratek Pharmaceuticals, Inc.
DEINOVE
BlueWillow Biologics.
GC Biopharma, corp.
Altimmune
TABLE OF CONTENTS
1 INTRODUCTION 75
1.1 OBJECTIVES OF THE STUDY 75
1.2 MARKET DEFINITION 75
1.3 OVERVIEW OF THE GLOBAL ANTHRAX TREATMENT MARKET 75
1.4 LIMITATIONS 77
1.5 MARKETS COVERED 77
2 MARKET SEGMENTATION 80
2.1 MARKETS COVERED 80
2.2 GEOGRAPHICAL SCOPE 81
2.3 YEARS CONSIDERED FOR THE STUDY 82
2.4 CURRENCY AND PRICING 82
2.5 DBMR TRIPOD DATA VALIDATION MODEL 83
2.6 MULTIVARIATE MODELLING 86
2.7 PRODUCT SEGMENT LIFELINE CURVE 86
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 87
2.9 DBMR MARKET POSITION GRID 88
2.10 MARKET APPLICATION COVERAGE GRID 89
2.11 VENDOR SHARE ANALYSIS 90
2.12 SECONDARY SOURCES 91
2.13 ASSUMPTIONS 91
3 EXECUTIVE SUMMARY 92
4 PREMIUM INSIGHTS 96
4.1 PESTEL ANALYSIS 98
4.2 PORTERS FIVE FORCES 99
4.3 DEMOGRAPHIC TRENDS- 100
4.4 EPIDEMIOLOGY AND DEMOGRAPHICS- 102
4.4.1 INCIDENCE 102
4.4.2 DEVELOPED COUNTRIES- 102
4.4.3 DEVELOPING COUNTRIES- 102
4.5 PATIENT ENROLMENT STRATEGIES- 104
4.6 PATIENT FLOW DIAGRAM FOR ANTHRAX INFECTION- 108
4.7 CURRENT STATE OF ANTHRAX VACCINES 110
4.8 GLOBAL ANTIBIOTIC CONSUMPTION RATES INCREASED BY 46 PERCENT IN THE LAST TWO DECADES, ACCORDING TO THE FIRST STUDY TO PROVIDE LONGITUDINAL ESTIMATES FOR HUMAN ANTIBIOTIC CONSUMPTION COVERING 204 COUNTRIES FROM 2000 TO 2018. 114
4.9 GLOBAL ANTIBIOTIC CONSUMPTION AND PROJECTED CONSUMPTION- 115
5 THE M&A IN THE ANTHRAX MARKET INDICATES AN UPCOMING LONG RUN IN VACCINE DEVELOPMENT AROUND THE GLOBE. CURRENT AND SOME OF LAST YEARS ACQUISITION BETWEEN LEADERS AND SMALL SIZE PHARMACEUTICAL SHOWS THE CONTINUOUS DEVELOPMENT IN THE COMPANYS PIPELINE FOR ANTHRAX TREATMENT. 119
6 GLOBAL ANTHRAX TREATMENT MARKET: REGULATIONS 121
7 MARKET OVERVIEW 125
7.1 DRIVERS 127
7.1.1 INCREASING INCIDENCE OF ANTHRAX INFECTION 127
7.1.2 INCREASE IN RESEARCH FUNDING AND THE DEVELOPMENT OF NOVEL THERAPIES FOR THE TREATMENT OF ANTHRAX 127
7.1.3 TECHNOLOGICAL ADVANCEMENTS IN TREATMENT PROCEDURE 128
7.1.4 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS 128
7.2 RESTRAINTS 129
7.2.1 HIGH COST ASSOCIATED WITH ANTHRAX DIAGNOSTIC TREATMENT 129
7.2.2 FALSE DATA INTERPRETATION 130
7.3 OPPORTUNITIES 130
7.3.1 RISING PRODUCT LAUNCHES 130
7.3.2 RISING GOVERNMENT INITIATIVES 131
7.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM 131
7.4 CHALLENGES 132
7.4.1 LACK OF AWARENESS AMONG PEOPLE ABOUT ANTHRAX INFECTION 132
7.4.2 LACK OF SKILLED PROFESSIONALS 132
8 GLOBAL ANTHRAX TREATMENT MARKET, BY TYPE 134
8.1 OVERVIEW 135
8.2 CUTANEOUS ANTHRAX 138
8.2.1 ANTIBIOTICS 139
8.2.1.1 BY DRUGS 139
8.2.1.1.1 CIPROFLOXACIN 140
8.2.1.1.2 LEVOFLOXACIN 140
8.2.1.1.3 DOXYCYCLINE 140
8.2.1.1.4 AMPICILLIN 140
8.2.1.1.5 OTHERS 140
8.2.1.2 BY PRODUCT TYPES 140
8.2.1.2.1 GENERICS 140
8.2.1.2.2 BRANDED 140
8.2.1.2.2.1 CIPRO 141
8.2.1.2.2.2 LEVO 141
8.2.1.2.2.3 DOXY 141
8.2.1.2.2.4 AMPICI 141
8.2.1.2.2.5 OTHERS 141
8.2.2 ANTITOXINS 142
8.2.2.1 RAXIBACUMAB 142
8.2.2.2 OBILTOXAXIMAB (ANTHIM) 142
8.2.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 142
8.2.2.4 OTHERS 142
8.2.3 VACCINES 143
8.2.3.1 RAXIBACUMAB 143
8.2.4 SURGERY 143
8.3 PULMONARY ANTHRAX 143
8.3.1 ANTIBIOTICS 144
8.3.1.1 BY DRUGS 145
8.3.1.1.1 CIPROFLOXACIN 145
8.3.1.1.2 LEVOFLOXACIN 145
8.3.1.1.3 DOXYCYCLINE 145
8.3.1.1.4 AMPICILLIN 145
8.3.1.1.5 OTHERS 145
8.3.1.2 BY PRODUCT TYPES 146
8.3.1.2.1 GENERICS 146
8.3.1.2.2 BRANDED 146
8.3.1.2.2.1 CIPRO 146
8.3.1.2.2.2 LEVO 147
8.3.1.2.2.3 DOXY 147
8.3.1.2.2.4 AMPICI 147
8.3.1.2.2.5 OTHERS 147
8.3.2 ANTITOXINS 147
8.3.2.1 RAXIBACUMAB 147
8.3.2.2 OBILTOXAXIMAB (ANTHIM) 147
8.3.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 147
8.3.2.4 OTHERS 148
8.3.3 VACCINES 148
8.3.3.1 RAXIBACUMAB 148
8.3.3.2 SURGERY 148
8.4 INTESTINAL ANTHRAX 148
8.4.1 ANTIBIOTICS 150
8.4.1.1 BY DRUGS 150
8.4.1.1.1 CIPROFLOXACIN 150
8.4.1.1.2 LEVOFLOXACIN 150
8.4.1.1.3 DOXYCYCLINE 150
8.4.1.1.4 AMPICILLIN 151
8.4.1.1.5 OTHERS 151
8.4.1.2 BY PRODUCT TYPES 151
8.4.1.2.1 GENERICS 151
8.4.1.2.2 BRANDED 151
8.4.1.2.2.1 CIPRO 152
8.4.1.2.2.2 LEVO 152
8.4.1.2.2.3 DOXY 152
8.4.1.2.2.4 AMPICI 152
8.4.1.2.2.5 OTHERS 152
8.4.2 ANTITOXINS 153
8.4.2.1 RAXIBACUMAB 153
8.4.2.2 OBILTOXAXIMAB (ANTHIM) 153
8.4.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 153
8.4.2.4 OTHERS 153
8.4.3 VACCINES 154
8.4.3.1 RAXIBACUMAB 154
8.4.3.2 SURGERY 154
9 GLOBAL ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 155
9.1 OVERVIEW 156
9.2 PARENTERAL 159
9.3 ORAL 159
9.4 OTHERS 160
10 GLOBAL ANTHRAX TREATMENT MARKET, BY END USER 161
10.1 OVERVIEW 162
10.2 GOVERNMENT ORGANIZATION 165
10.3 HOSPITALS 165
10.4 ACADEMIC AND RESEARCH 166
10.5 OTHERS 168
11 GLOBAL VIRTUAL REALITY MARKET, BY GEOGRAPHY 169
11.1 GLOBAL 170
11.2 NORTH AMERICA 175
11.2.1 U.S. 192
11.2.2 CANADA 202
11.2.3 MEXICO 212
11.3 MIDDLE EAST AND AFRICA 222
11.3.1 SOUTH AFRICA 239
11.3.2 SAUDI ARABIA 248
11.3.3 UAE 257
11.3.4 EGYPT 266
11.3.5 ISRAEL 275
11.3.6 REST OF MIDDLE EAST AND AFRICA 284
11.4 EUROPE 285
11.4.1 GERMANY 301
11.4.2 FRANCE 312
11.4.3 U.K. 322
11.4.4 ITALY 333
11.4.5 RUSSIA 344
11.4.6 SPAIN 354
11.4.7 TURKEY 364
11.4.8 NETHERLANDS 374
11.4.9 SWITZERLAND 385
11.4.10 BELGIUM 396
11.4.11 REST OF EUROPE 407
11.5 ASIA-PACIFIC 408
11.5.1 CHINA 424
11.5.2 JAPAN 435
11.5.3 SOUTH KOREA 446
11.5.4 INDIA 457
11.5.5 AUSTRALIA 468
11.5.6 SINGAPORE 479
11.5.7 THAILAND 490
11.5.8 MALAYSIA 501
11.5.9 INDONESIA 512
11.5.10 PHILIPPINES 522
11.5.11 REST OF ASIA-PACIFIC 533
11.6 SOUTH AMERICA 534
11.6.1 BRAZIL 549
11.6.2 ARGENTINA 560
11.6.3 REST OF SOUTH AMERICA 571
12 GLOBAL ANTHRAX TREATMENT MARKET, COMPANY LANDSCAPE 572
12.1 COMPANY SHARE ANALYSIS: GLOBAL 572
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 573
12.3 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 574
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 575
13 SWOT ANALYSIS 576
14 COMPANY PROFILE 577
14.1 BAYER AG 577
14.1.1 COMPANY SNAPSHOT 577
14.1.2 REVENUE ANALYSIS 577
14.1.3 COMPANY SHARE ANALYSIS 578
14.1.4 PRODUCT PORTFOLIO 578
14.1.5 RECENT DEVELOPMENTS 578
14.2 PFIZER INC. 579
14.2.1 COMPANY SNAPSHOT 579
14.2.2 REVENUE ANALYSIS 579
14.2.3 COMPANY SHARE ANALYSIS 580
14.2.4 PRODUCT PORTFOLIO 580
14.2.5 RECENT DEVELOPMENTS 580
14.3 TEVA PHARMACEUTICAL INDUSTRIES LTD 581
14.3.1 COMPANY SNAPSHOT 581
14.3.2 REVENUE ANALYSIS 581
14.3.3 COMPANY SHARE ANALYSIS 582
14.3.4 PRODUCT PORTFOLIO 582
14.3.5 RECENT DEVELOPMENT 582
14.4 SANOFI 583
14.4.1 COMPANY SNAPSHOT 583
14.4.2 REVENUE ANALYSIS 583
14.4.3 COMPANY SHARE ANALYSIS 584
14.4.4 PRODUCT PORTFOLIO 584
14.4.5 RECENT DEVELOPMENTS 584
14.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED. 585
14.5.1 COMPANY SNAPSHOT 585
14.5.2 REVENUE ANALYSIS 585
14.5.3 PRODUCT PORTFOLIO 586
14.5.4 RECENT DEVELOPMENT 586
14.6 ALEMBIC PHARMACEUTICALS LIMITED 587
14.6.1 COMPANY SNAPSHOT 587
14.6.2 PRODUCT PORTFOLIO 587
14.6.3 RECENT DEVELOPMENTS 587
14.7 ALTIMMUNE 588
14.7.1 COMPANY SNAPSHOT 588
14.7.2 REVENUE ANALYSIS 588
14.7.3 PRODUCT PORTFOLIO 589
14.7.4 RECENT DEVELOPMENTS 589
14.8 ARISTO PHARMACEUTICALS PRIVATE LIMITED 590
14.8.1 COMPANY SNAPSHOT 590
14.8.2 PRODUCT PORTFOLIO 590
14.8.3 RECENT DEVELOPMENTS 590
14.9 BLUEWILLOW BIOLOGICS. 591
14.9.1 COMPANY SNAPSHOT 591
14.9.2 PRODUCT PORTFOLIO 591
14.9.3 RECENT DEVELOPMENTS 591
14.10 DEINOVE 592
14.10.1 COMPANY SNAPSHOT 592
14.10.2 REVENUE ANALYSIS 592
14.10.3 PRODUCT PORTFOLIO 593
14.10.4 RECENT DEVELOPMENTS 593
14.11 EMERGENT 594
14.11.1 COMPANY SNAPSHOT 594
14.11.2 REVENUE ANALYSIS 594
14.11.3 PRODUCT PORTFOLIO 595
14.11.4 RECENT DEVELOPMENTS 595
14.12 ELUSYS THERAPEUTICS INC. 596
14.12.1 COMPANY SNAPSHOT 596
14.12.2 PRODUCT PORTFOLIO 596
14.12.3 RECENT DEVELOPMENTS 596
14.13 GC BIOPHARMA CORP. 597
14.13.1 COMPANY SNAPSHOT 597
14.13.2 REVENUE ANALYSIS 597
14.13.3 PRODUCT PORTFOLIO 598
14.13.4 RECENT DEVELOPMENTS 598
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
